Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Liabilities and Shareholders Equity (2012 - 2026)

Updated

Grace Therapeutics' Liabilities and Shareholders Equity came in at $57.7 million for fiscal Q2 2027 (quarter ended Sep 30, 2026), down 13.3% from $66.58 million a year earlier but up 15.2% from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends

At the end of FY2026 (ended Mar 31, 2026), Grace Therapeutics' Liabilities and Shareholders Equity was $66.65 million, down 7.4% from FY2025.

  • Liabilities and Shareholders Equity has declined in each of the last four fiscal years, though with a five-year compound annual growth rate of 1.3% (FY2021 to FY2026).
  • Going back by fiscal year, Liabilities and Shareholders Equity was $71.99 million in FY2025 (-1.8%), $73.3 million in FY2024 (-7.4%), $79.12 million in FY2023 (-38.5%) and $128.62 million in FY2022 (+105.9%).
  • The five-year range for quarterly Liabilities and Shareholders Equity is $50.07 million (fiscal Q1 2027) to $128.62 million (fiscal Q4 2022).
  • Year-over-year, Liabilities and Shareholders Equity has declined for three consecutive quarters, with an average decline of 7.1% over the last eight quarters.
  • The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in fiscal Q3 2022 (growth of 276.9%), and the weakest in fiscal Q1 2024 (a decline of 41.5%).
  • Business Quant data shows GRCE's Liabilities and Shareholders Equity at $50.07 million (Q1 2027), $66.65 million (Q4 2026) and $68.49 million (Q3 2026) in the three fiscal quarters before Q2 2027.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 148.07 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 197.43 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 147.68 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 132.77 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 119.92 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 96.05 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 51.41 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 205.00 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn - 57.70 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 57.70 Mn
Jun 30, 2026 50.07 Mn
Mar 31, 2026 66.65 Mn
Dec 31, 2025 68.49 Mn
Sep 30, 2025 66.58 Mn
Jun 30, 2025 69.81 Mn
Mar 31, 2025 71.99 Mn
Dec 31, 2024 61.22 Mn
Sep 30, 2024 65.35 Mn
Jun 30, 2024 69.72 Mn
Mar 31, 2024 73.30 Mn
Dec 31, 2023 76.19 Mn
Sep 30, 2023 78.21 Mn
Jun 30, 2023 73.03 Mn
Mar 31, 2023 79.12 Mn
Dec 31, 2022 116.80 Mn
Sep 30, 2022 120.91 Mn
Jun 30, 2022 124.93 Mn
Mar 31, 2022 128.62 Mn
Dec 31, 2021 114.23 Mn
API Access

Grace Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=GRCE&period=max&api_key=YOUR_API_KEY